Giulia Arrivi

13PUBLICATIONS
47CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsNeurology and neuromuscular diseasesCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 22, 2026
On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.

|Dec 11, 2025
Radiomic and Clinical-Pathological Factors Predictive of Postoperative Recurrence in Lung Neuroendocrine Tumors: A Pilot Study.

Piero Paravani, Michela Polici, Giulia Arrivi

|Dec 11, 2025
FBXW7 Gene Mutation and Expression in Colorectal Cancer (CRC): A Systematic Review from Molecular Mechanisms to Clinical Translation.

Giulia Arrivi, Gabriella Gentile, Michela Roberto

|Oct 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Carlo Signorelli, Michele Basso, Maria Alessandra Calegari

|Jun 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

|Dec 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

Pageof 3

Frequent Collaborators

5 joint publications

Fiorenza Santamaria

4 joint publications

Carlo Signorelli

4 joint publications

Emanuela Dell'Aquila

4 joint publications

Ina Valeria Zurlo